BioNTech SE
BNTX
|
News
|
$88.01
1.38%
1.36%
390K
|
Health Technology
(0.0% 1d) (-5.4% 1m) (-24.7% 1y) (0.0% 2d) (0.0% 3d) (2.1% 7d) (Infinity% volume)
Earnings Calendar:
Market Cap: $ 20,922,241,937
http://www.biontech.de
Sec Filling | Patents | 1310 employees
BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.
diagnostics msa dividends
add to watch list Paper trade email alert is off
Press-releases
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Published: 2024-04-22 (Crawled : 11:00) - globenewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 1.33%
H: 2.12%
C: 1.3%
first report update financial results
Understanding the mRNA Therapeutics Market's -8.6% Decline: Insights from BCC Research
Published: 2024-04-10 (Crawled : 14:30) - prnewswire.com
OMGA | $2.39 -0.42% -0.42% 190K
|
|
| O: -0.33%
H: 0.17%
C: 0.0%
CVAC | $2.525 3.48% 3.37% 600K
|
Health Technology
|
| O: -0.67%
H: 1.36%
C: 0.0%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -1.69%
H: 0.97%
C: 0.14%
mrna research therapeutics
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
Published: 2024-04-07 (Crawled : 20:20) - globenewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 1.38%
H: 0.2%
C: -1.27%
candidate cancer pancreatic tumor immunotherapy for response show
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Published: 2024-03-27 (Crawled : 20:00) - globenewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -0.08%
H: 1.01%
C: -0.7%
MTNB | $0.18 -4.1% 0.44% 1.4M
|
Health Technology
|
| O: -3.38%
H: 2.32%
C: -3.25%
business update biopharma financial results
BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
Published: 2024-03-20 (Crawled : 10:00) - globenewswire.com
NVSEF | News | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.37%
H: 0.0%
C: -1.58%
NVS | News | $95.12 0.81% -1.18% 2.4M
|
Health Technology
|
| O: -0.62%
H: 0.45%
C: 0.34%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -5.51%
H: 1.33%
C: 1.2%
management commercial
BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Published: 2024-03-20 (Crawled : 11:00) - biospace.com/
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: -5.51%
H: 1.33%
C: 1.2%
AUTL | $4.58 1.33% 1.31% 1.2M
|
Health Technology
|
| O: 1.45%
H: 5.33%
C: 4.13%
year update financial results
Lipid-Nanoparticle Based Genomic Medicines Market worth $32.5 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.
Published: 2024-03-18 (Crawled : 14:00) - prnewswire.com
CVAC | $2.525 3.48% 3.37% 600K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -2.73%
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.48%
H: 1.18%
C: 0.08%
ABUS | $2.645 -2.76% -2.84% 740K
|
Health Technology
|
| O: 0.38%
H: 0.38%
C: -3.42%
report genomic market
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.11%
H: 0.3%
C: -1.21%
AUTL | $4.58 1.33% 1.31% 1.2M
|
Health Technology
|
| O: 1.82%
H: 12.19%
C: 2.15%
business year therapeutics financial results
CTXTQ ALERT: Levi & Korsinsky, LLP Commences an Investigation of Cyxtera Technologies, Inc. (CYXTQ) f/k/a Starboard Value Acquisition (SVAC)
Published: 2024-03-12 (Crawled : 19:00) - prnewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.01%
H: 0.98%
C: -1.87%
acquisition
ALVR IMPORTANT DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important March 19 Deadline in Securities Class Action - ALVR
Published: 2024-03-12 (Crawled : 19:00) - prnewswire.com
BNTX | News | $88.01 1.38% 1.36% 390K
|
Health Technology
|
| O: 0.01%
H: 0.98%
C: -1.87%
ALVR | $0.7601 1.32% 1.3% 170K
|
Health Technology
|
| O: -0.14%
H: 1.49%
C: -1.43%
deadline global
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Last 48 Hours Insiders Buying
MCFT P 26039 | $21.5 1.9% 1.86% 110K
|
Consumer Durables
|
00:00
YORW P 29 | $35.43 1.03% 1.02% 66K
|
Utilities
|
19:01
VUZI P 14500 | $1.35 11.57% 10.37% 890K
|
Electronic Technology
|
17:00
BANF P 256 | $91.28 2.24% 2.18% 150K
|
Finance
|
15:30
RMCF | $3.56 0.28% 0.28% 11K
|
Consumer Non-Durables
|
20:10